Kang YK - Search Results

1

Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study.

Meric-Bernstam F, Beeram M, Hamilton E, Oh DY, Hanna DL, Kang YK, Elimova E, Chaves J, Goodwin R, Lee J, Nabell L, Rha SY, Mayordomo J, El-Khoueiry A, Pant S, Raghav K, Kim JW, Patnaik A, Gray T, Davies R, Ozog MA, Woolery J, Lee KW. Meric-Bernstam F, et al. Among authors: kang yk. Lancet Oncol. 2022 Dec;23(12):1558-1570. doi: 10.1016/S1470-2045(22)00621-0. Epub 2022 Nov 16. Lancet Oncol. 2022. PMID: 36400106 Clinical Trial.

2

Oral doxifluridine plus leucovorin in metastatic colorectal cancer: randomized phase II trial with intravenous 5-fluorouracil plus leucovorin.

Ahn JH, Kim TW, Lee JH, Min YJ, Kim JG, Kim JC, Yu CS, Kim WK, Kang YK, Lee JS. Ahn JH, et al. Among authors: kang yk. Am J Clin Oncol. 2003 Feb;26(1):98-102. doi: 10.1097/01.COC.0000017089.68491.1F. Am J Clin Oncol. 2003. PMID: 12576934 Clinical Trial.

3

Phase II study of paclitaxel and carboplatin in advanced gastric cancer previously treated with 5-fluorouracil and platinum.

Chang HM, Kim TW, Ryu BY, Choi SJ, Park YH, Lee JS, Kim WK, Kang YK. Chang HM, et al. Among authors: kang yk. Jpn J Clin Oncol. 2005 May;35(5):251-5. doi: 10.1093/jjco/hyi077. Epub 2005 May 10. Jpn J Clin Oncol. 2005. PMID: 15886269 Clinical Trial.

4

Combination chemotherapy with capecitabine (X) and Cisplatin (P) as first line treatment in advanced gastric cancer: experience of 223 patients with prognostic factor analysis.

Lee SS, Lee JL, Ryu MH, Chang HM, Kim TW, Kang HJ, Kim WK, Lee JS, Kang YK. Lee SS, et al. Among authors: kang hj, kang yk. Jpn J Clin Oncol. 2007 Jan;37(1):30-7. doi: 10.1093/jjco/hyl134. Jpn J Clin Oncol. 2007. PMID: 17272321

5

Phase II study of biweekly paclitaxel and cisplatin combination chemotherapy in advanced gastric cancer: Korea Japan Collaborative Study Group Trial.

Kim YH, Yamaguchi K, Bang YJ, Takiuchi H, Kang WK, Sato A, Kang YK, Sakamoto J, Abe C, Sakata Y. Kim YH, et al. Among authors: kang wk, kang yk. Jpn J Clin Oncol. 2007 Jul;37(7):501-8. doi: 10.1093/jjco/hym054. Epub 2007 Aug 2. Jpn J Clin Oncol. 2007. PMID: 17673470 Clinical Trial.

6

Docetaxel monotherapy as a second-line treatment after failure of fluoropyrimidine and platinum in advanced gastric cancer: experience of 154 patients with prognostic factor analysis.

Jo JC, Lee JL, Ryu MH, Sym SJ, Lee SS, Chang HM, Kim TW, Lee JS, Kang YK. Jo JC, et al. Among authors: kang yk. Jpn J Clin Oncol. 2007 Dec;37(12):936-41. doi: 10.1093/jjco/hym123. Jpn J Clin Oncol. 2007. PMID: 18211985

7

Salvage chemotherapy with biweekly irinotecan, plus 5-fluorouracil and leucovorin in patients with advanced gastric cancer previously treated with fluoropyrimidine, platinum, and taxane.

Sym SJ, Ryu MH, Lee JL, Chang HM, Kim TW, Lee SS, Lee JS, Kang YK. Sym SJ, et al. Among authors: kang yk. Am J Clin Oncol. 2008 Apr;31(2):151-6. doi: 10.1097/COC.0b013e31815878a2. Am J Clin Oncol. 2008. PMID: 18391599

8

Capecitabine in the treatment of advanced gastric cancer.

Lee JL, Kang YK. Lee JL, et al. Among authors: kang yk. Future Oncol. 2008 Apr;4(2):179-98. doi: 10.2217/14796694.4.2.179. Future Oncol. 2008. PMID: 18407732 Review.

9

A prospective, multicenter, phase 2 study of imatinib mesylate in korean patients with metastatic or unresectable gastrointestinal stromal tumor.

Ryu MH, Kang WK, Bang YJ, Lee KH, Shin DB, Ryoo BY, Roh JK, Kang JH, Lee H, Kim TW, Chang HM, Park JO, Park YS, Kim TY, Kim MK, Lee WK, Kang HJ, Kang YK. Ryu MH, et al. Among authors: kang jh, kang wk, kang hj, kang yk. Oncology. 2009;76(5):326-32. doi: 10.1159/000209384. Epub 2009 Mar 23. Oncology. 2009. PMID: 19307738 Clinical Trial.

10

The role of KRAS mutations in predicting the efficacy of cetuximab-plus-irinotecan therapy in irinotecan-refractory Korean metastatic colorectal cancer patients.

Sohn BS, Kim TW, Lee JL, Ryu MH, Chang HM, Kang YK, Park HS, Na YS, Jang SJ, Kim JC, Lee JS. Sohn BS, et al. Among authors: kang yk. Oncology. 2009;77(3-4):224-30. doi: 10.1159/000236046. Epub 2009 Sep 7. Oncology. 2009. PMID: 19738388

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

794 results

Search Page

Filters